Exploring the use of seasonal malaria chemoprevention in South Sudan

In South Sudan, malaria accounts for 33 percent of all hospital admissions and is the leading cause of mortality in children under five. We recently conducted implementation research in Uganda and Mozambique, demonstrating that malaria cases were significantly less likely to occur in areas that received SMC compared to those that did not, and that SMC is feasible, acceptable and safe. The study seeks to understand the feasibility, acceptability and impact of implementing SMC in Aweil South Country, to determine the chemoprevention efficacy of SMC medicines, and to explore the scalability of SMC in other states in South Sudan.

Click here to download

Country: South Sudan